Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and Apoptosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Ellagitannins (ETs) from pomegranate juice (PJ) are bioactive polyphenols with chemopreventive potential against prostate cancer (PCa). ETs are not absorbed intact but are partially hydrolyzed in the gut to ellagic acid (EA). Colonic microflora can convert EA to urolithin A (UA), and EA and UA enter the circulation after PJ consumption. Here, we studied the effects of EA and UA on cell proliferation, cell cycle, and apoptosis in DU-145 and PC-3 androgen-independent PCa cells and whether combinations of EA and UA affected cell proliferation. EA demonstrated greater dose-dependent antiproliferative effects in both cell lines compared to UA. EA induced cell cycle arrest in S phase associated with decreased cyclin B1 and cyclin D1 levels. UA induced a G2/M arrest and increased cyclin B1 and cdc2 phosphorylation at tyrosine-15, suggesting inactivation of the cyclin B1/cdc2 kinase complex. EA induced apoptosis in both cell lines, while UA had a less pronounced proapoptotic effect only in DU-145. Cotreatment with low concentrations of EA and UA dramatically decreased cell proliferation, exhibiting synergism in PC-3 cells evaluated by isobolographic analysis and combination index. These data provide information on pomegranate metabolites for the prevention of PCa recurrence, supporting the role of gut flora-derived metabolites for cancer prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Cerdá, B., Periago, P., Espín, J. C., & Tomás-Barberán, F. A. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf050384i · Cited by 301 · cited 2×
“EA is partially converted in the intestine into other bioactive metabolites, including UA which is metabolized by phase II enzymes and excreted in human urine for up to 48 hours after consumption of PJ [8, 10, 11].”
Cited by
Rodriguez-Mateos, A., Vauzour, D., Krueger, C. G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., & Crozier, A. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1330-7 · Cited by 602
Tomás‐Barberán, F. A., González‐Sarrías, A., García‐Villalba, R., Núñez‐Sánchez, M. A., Selma, M. V., García‐Conesa, M. T., & Espín, J. C. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500901 · Cited by 465
A Pharmacological Update of Ellagic Acid
Ríos, J.-L., Giner, R., Marín, M., & Recio, M. (2018) · Planta Medica · doi:10.1055/a-0633-9492 · Cited by 413
Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
Ceci, C., Lacal, P. M., Tentori, L., De Martino, M. G., Miano, R., & Graziani, G. (2018) · Nutrients · doi:10.3390/nu10111756 · Cited by 255
Wu, S., & Tian, L. (2017) · Molecules · doi:10.3390/molecules22101606 · Cited by 235
Metadata
- Authors
- Vicinanza, R., Zhang, Y., Henning, S. M., & Heber, D.
- Venue
- Evidence-Based Complementary and Alternative Medicine
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-12
- ISSN
- 1741-427X (ISSN-L)
- 1741-4288
- OpenAlex
- W2063880990
- Cited by
- 97
- References
- 4
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.